Bristol-Myers Squibb
2021-07-19 2:55 pm
| Sydney
Merck Sharp & Dohme has filed a lawsuit accusing rival drug company Bristol-Myers Squibb of misusing its market power by restricting access to a treatment program for stage IV melanoma patients.